Medicine and Dentistry
Adverse Event
100%
Patient Characteristics
83%
Observational Study
50%
Medication Error
50%
Clinical Prediction Model
50%
Systematic Review
50%
Monoclonal Antibody
50%
Parasitic Disease
50%
Odds Ratio
41%
Reslizumab
33%
Benralizumab
33%
Health Outcomes
25%
Meta-Analysis
25%
Mepolizumab
25%
Cytokine
25%
Dupilumab
25%
Omalizumab
25%
MedDRA
20%
Population Size
16%
Patient Care
16%
Immunoglobulin E
16%
Adalimumab
12%
Immunomodulating Agent
12%
Public Health
12%
Antineoplastic Agent
12%
Parasitic Disease
8%
Interleukin 5
8%
Interleukin 4 Receptor
8%
Cytokine Receptor
8%
Biological Product
8%
Inflammatory Disorder
8%
Quality of Life
8%
Helminthiasis
8%
Asthma
8%
Dermatitis
8%
Urticaria
8%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Medication Error
100%
Disproportionality Analysis
100%
Monoclonal Antibody
50%
Infection
50%
Benralizumab
33%
Reslizumab
33%
Mepolizumab
25%
Omalizumab
25%
Cytokine
25%
Dupilumab
25%
MedDRA
24%
Safety Case
21%
Immunoglobulin E
16%
Adalimumab
12%
Immunomodulating Agent
12%
Antineoplastic Agent
12%
Parasitosis
8%
Cytokine Receptor
8%
Interleukin 4 Receptor
8%
Asthma
8%
Biological Product
8%
Interleukin 5
8%
Dermatitis
8%
Urticaria
8%
Inflammatory Disease
8%
Helminthiasis
8%
Risperidone
7%
Oxycodone
7%
Rivaroxaban
7%
